BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PYZCHIVA (ustekinumab-ttwe) by Samsung Bioepis is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 34m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYZCHIVA (ustekinumab-ttwe) is a biosimilar monoclonal antibody targeting interleukin-12, a cytokine involved in immune-mediated inflammatory diseases. It blocks IL-12 signaling to reduce pathogenic immune responses. As a biosimilar, it references the originator ustekinumab and is indicated for the same conditions.
Growth
Recent approval positions PYZCHIVA in active growth phase; biosimilar entry strategy will drive market share gains, requiring lean, agile commercial teams focused on payer negotiation and provider education.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PYZCHIVA offers exposure to biosimilar market dynamics, payer negotiation, and rapid market penetration strategy—skills highly valued in the evolving biologics landscape. The product is in active growth post-launch, creating near-term opportunities in market access and field force roles, though limited clinical pipeline work may reduce clinical career development.
Brand Manager
Worked on PYZCHIVA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.